IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

Conditions: FIGO Stage III and IV Ovarian Cancer; FIGO Stage III and IV Fallopian Tube Cancer; FIGO Stage III Primary Peritoneal Cancer
Interventions: Biological: ALT-803 Subcutaneous; Biological: ALT-803 Intraperitoneal
Sponsors: Masonic Cancer Center, University of Minnesota
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 14, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments